HDAC Inhibitors as a Treatment for Fibrotic and Inflammatory Diseases
Author Information
Author(s): Theodoropoulou Maria A., Mantzourani Christiana, Kokotos George
Primary Institution: National and Kapodistrian University of Athens
Hypothesis
Can HDAC inhibitors be effective in treating fibrotic and inflammatory diseases beyond cancer?
Conclusion
HDAC inhibitors show promise as therapeutic agents for fibrotic and inflammatory diseases, with ongoing research needed to optimize their use.
Supporting Evidence
- HDAC inhibitors have been traditionally used for cancer treatment but are now being explored for other diseases.
- Recent studies indicate that HDACs play a role in various fibrotic and inflammatory diseases.
- Selective HDAC inhibitors may reduce side effects compared to pan-HDAC inhibitors.
Takeaway
Scientists are studying special medicines called HDAC inhibitors that might help treat diseases where the body makes too much scar tissue or gets inflamed.
Methodology
This perspective article reviews recent studies on HDAC inhibitors as anti-fibrotic and anti-inflammatory agents from 2020 to 2024.
Potential Biases
Potential bias may arise from the focus on specific HDAC inhibitors and their effects without comprehensive comparisons to other treatment options.
Limitations
The broad-spectrum effects of HDAC inhibitors can lead to significant side effects, necessitating the development of more selective inhibitors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website